SEVERE SEROTONIN SYNDROME AFTER ANTIDEPRESSANT USE SUCCESSFULLY TREATED WITH TARGETED TEMPERATURE MANAGEMENT

Authors

  • The Minh Tung Nguyen Author
  • Minh Hoa Le Author
  • Van Thang Le Author
  • Dai Khanh Do Author
  • Tan Hung Nguyen Author

Keywords:

Serotonin syndrome, malignant hyperthermia, rhabdomyolysis, targeted temperature management

Abstract

Serotonin syndrome is an acute, potentially life-threatening toxic condition resulting from excessive serotonergic activity in the central nervous system. It most commonly occurs after the use of antidepressants, particularly selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, or in combination with other serotonergic agents. The typical clinical presentation consists of a triad of altered mental status, neuromuscular hyperactivity, and autonomic dysfunction. In severe cases, the condition may rapidly progress to malignant hyperthermia, rhabdomyolysis, multiorgan failure, and death if not promptly recognized and treated. We report a case of severe serotonin syndrome in a 21-year-old female following sertraline use. The patient developed malignant hyperthermia (peak temperature 41°C), generalized hypertonia, ocular clonus, seizures, and rhabdomyolysis. Management included immediate discontinuation of the offending agent, intensive supportive care, and the implementation of Targeted Temperature Management (TTM) with a core temperature target of 37°C maintained for eight days. The patient demonstrated marked clinical improvement and achieved complete recovery. This case suggests that TTM may be a safe and effective therapeutic option in fulminant serotonin syndrome with refractory hyperthermia.

References

1. Chiew AL, Isbister GK. Management of serotonin syndrome (toxicity). Br J Clin Pharmacol. 2025;91(3):654-61. DOI:10.1111/bcp.16152

2. Wang RZ, Vashistha V, Kaur S, Houchens NW. Serotonin syndrome: preventing, recognizing, and treating it. Cleve Clin J Med. 2016;83(11):810-7. DOI:10.3949/ccjm.83a.15129

3. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust. 2007;187(6):361-5. DOI:10.5694/j.1326-5377.2007.tb01282.x

4. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000;79(4):201-9. DOI:10.1097/00005792-200007000-00001

5. Werneke U, Jamshidi F, Taylor DM, Ott M. Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases. BMC Neurol. 2016;16:97. DOI:10.1186/s12883-016-0616-1

6. Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions. Int J Tryptophan Res. 2019;12:1178646919873925. DOI:10.1177/1178646919873925

7. Yoshidome A, Yamasato K, Harada T, Ozawa H, Inoue T, Nakai M. Ocular clonus. J Am Coll Emerg Physicians Open. 2023;4(5):e13055. DOI:10.1002/emp2.13055

8. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-20. DOI:10.1056/nejmra041867

9. McDaniel WW. Serotonin syndrome: early management with cyproheptadine. Ann Pharmacother. 2001;35(7-8):870-3. DOI:10.1345/aph.10203

10. Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013;13(4):533-40. DOI:10.1007/978-1-4614-8948-1_49

11. Eyer F, Zilker T. Bench-to-bedside review: mechanisms and management of hyperthermia due to toxicity. Crit Care. 2007;11(6):236. DOI:10.1186/cc6177

12. Krishnamoorthy S, Ma Z, Zhang G, Wei J, Auerbach SB, Tao R. Involvement of 5-HT2A receptors in the serotonin (5-HT) syndrome caused by excessive 5-HT efflux in rat brain. Basic Clin Pharmacol Toxicol. 2010;107(4):830-41. DOI:10.1111/j.1742-7843.2010.00586.x

Published

16-05-2026

How to Cite

SEVERE SEROTONIN SYNDROME AFTER ANTIDEPRESSANT USE SUCCESSFULLY TREATED WITH TARGETED TEMPERATURE MANAGEMENT. (2026). DA NANG JOURNAL OF MEDICINE AND PHARMACY, 2(2), 123-130. https://tapchi.ydn.edu.vn/index.php/yduoc/article/view/36

Similar Articles

You may also start an advanced similarity search for this article.